tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

KDNY

Novartis completes acquisition of Chinook Therapeutics
The FlyNovartis completes acquisition of Chinook Therapeutics
11M ago
NVS
KDNY
Wedbush downgrades Chinook Therapeutics to Neutral as acquisition draws closer
PremiumThe Fly
Wedbush downgrades Chinook Therapeutics to Neutral as acquisition draws closer
12M ago
NVS
KDNY
Chinook Therapeutics downgraded to Neutral from Outperform at Wedbush
PremiumThe Fly
Chinook Therapeutics downgraded to Neutral from Outperform at Wedbush
12M ago
KDNY
Chinook Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
PremiumThe Fly
Chinook Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
12M ago
KDNY
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
PremiumPress Releases
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
12M ago
KDNY
Chinook announces first patient enrolled in Phase 3 BEYOND study of BION-1301
PremiumThe FlyChinook announces first patient enrolled in Phase 3 BEYOND study of BION-1301
12M ago
KDNY
Chinook Therapeutics presents data from CHK-336 Phase 1 trial
PremiumThe Fly
Chinook Therapeutics presents data from CHK-336 Phase 1 trial
1y ago
KDNY
Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
PremiumPress Releases
Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
1y ago
KDNY
Chinook Therapeutics downgraded to In Line from Outperform at Evercore ISI
PremiumThe Fly
Chinook Therapeutics downgraded to In Line from Outperform at Evercore ISI
1y ago
KDNY
Chinook Therapeutics downgraded to Hold from Buy at Stifel
PremiumThe Fly
Chinook Therapeutics downgraded to Hold from Buy at Stifel
1y ago
KDNY
Chinook Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Chinook Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
1y ago
KDNY
Chinook downgraded to Market Perform from Outperform at SVB Securities
PremiumThe Fly
Chinook downgraded to Market Perform from Outperform at SVB Securities
1y ago
KDNY
Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
PremiumPress ReleasesChinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
1y ago
KDNY
Lexicon has ‘only un-partnered asset’ in SGLT2i space, says Piper
PremiumThe Fly
Lexicon has ‘only un-partnered asset’ in SGLT2i space, says Piper
1y ago
NVS
KDNY
Chinook Therapeutics downgraded to Neutral from Buy at Guggenheim
PremiumThe Fly
Chinook Therapeutics downgraded to Neutral from Buy at Guggenheim
1y ago
KDNY
Chinook Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
PremiumThe Fly
Chinook Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
1y ago
KDNY
Chinook downgraded to Market Perform from Outperform at William Blair
PremiumThe Fly
Chinook downgraded to Market Perform from Outperform at William Blair
1y ago
NVS
KDNY
Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease
PremiumPress Releases
Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease
1y ago
KDNY
KDNY Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
KDNY Upcoming Earnings Report: What to Expect?
1y ago
KDNY
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress ReleasesChinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1y ago
KDNY
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress
PremiumPress Releases
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress
1y ago
KDNY
Chinook Therapeutics price target lowered to $35 from $43 at Guggenheim
PremiumThe Fly
Chinook Therapeutics price target lowered to $35 from $43 at Guggenheim
1y ago
KDNY
TVTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >